Tokai Pharmaceuticals to Participate in Upcoming Investment Conferences

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that Martin D. Williams, president and chief executive officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Tuesday, February 26, 2013 at 9:00 a.m. (ET) in New York City. Mr. Williams will present an overview of the company and its lead prostate cancer candidate galeterone (TOK-001).